Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from ...

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or ...

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

The U.S. Food and Drug Administration (FDA) is changing the game on COVID-19 vaccines. Instead of approving yearly boosters ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans, a move that may limit ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

FDA FLAGS SEVERE ITCH — Patients who stop using the oral allergy medicines cetirizine (Zyrtec) or levocetirizine (Xyzal) may ...